Inventor · disambiguated record
Olga Ignatovich
Also filed as: IGNATOVICH OLGA
20 granted patents·21 pending applications·156 citations·filing 2003–2024
95Inventor score
Files withDOMANTIS LTD13AGENUS INC12BRISTOL MYERS SQUIBB CO10MCKINNON MURRAY3SMITHKLINE BEECHAM CORP1
Top patents by PatentIndex Score
41 records- 0194US11242385B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Feb 8, 2022·8 cites·24 claims
- 0294US8895010B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Nov 25, 2014·24 cites·36 claims
- 0393US8454959B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jun 4, 2013·23 cites·11 claims
- 0493US8168759B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2009·Granted May 1, 2012·21 cites·13 claims
- 0592US9085629B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jul 21, 2015·18 cites·29 claims
- 0692US7696320B2Ligands that have binding specificity for VEGF and/or EGFR and methods of use thereforDOMANTIS LTD·Filed 2006·Granted Apr 13, 2010·25 cites·65 claims
- 0791US10919965B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 16, 2021·3 cites·18 claims
- 0891US9228018B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 5, 2016·11 cites·35 claims
- 0988US9908937B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 6, 2018·5 cites·22 claims
- 1088US9765150B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 19, 2017·5 cites·37 claims
- 1188US8981072B2Nucleic acids encoding antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Mar 17, 2015·8 cites·27 claims
- 1285US11692042B2Anti-CD73 antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Jul 4, 2023·3 cites·22 claims
- 1379US11680098B2Antibodies that specifically bind human CD96AGENUS INC·Filed 2020·Granted Jun 20, 2023·1 cites·22 claims
- 1478US12492393B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Dec 9, 2025·0 cites·28 claims
- 1578US10196451B2Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40LBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 5, 2019·1 cites·20 claims
- 1678US2022073636A1Antibody polypeptides that antagonize cd40lBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1776US12012452B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jun 18, 2024·0 cites·20 claims
- 1874US11098117B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 24, 2021·0 cites·25 claims
- 1974US2022106581A1Anti-cd137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 2071US11180567B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 23, 2021·0 cites·20 claims
- 2170US2023416397A1Anti-cd73 antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 2267US12479913B2Polynucleotide encoding anti-TIGIT and anti-CD96 antibodiesAGENUS INC·Filed 2023·Granted Nov 25, 2025·0 cites·23 claims
- 2366US2024209082A1Anti-cd96 antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 2465US11718669B2Anti-TIGIT and anti-CD96 antibodiesAGENUS INC·Filed 2022·Granted Aug 8, 2023·0 cites·37 claims
- 2563US2025109201A1Anti-ilt2 antibodies and uses thereofAGENUS INC·Filed 2024·Application pending·0 cites
- 2658US2005271663A1Compositions and methods for treating inflammatory disordersDOMANTIS LTD·Filed 2004·Application pending·0 cites
- 2758US2006106203A1LigandDOMANTIS LTD·Filed 2004·Application pending·0 cites
- 2856US2009258012A1Compositions and methods for treating inflammatory disordersDOMANTIS LTD·Filed 2009·Application pending·0 cites
- 2956US2009081233A1Ligands that have binding specificity for VEGF and/or EGFR and methods of use thereforDOMANTIS LTD·Filed 2008·Application pending·0 cites
- 3056US2010081792A1LigandSMITHKLINE BEECHAM CORP·Filed 2007·Application pending·0 cites
- 3154US2022389095A1Anti-tigit antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3253US2010056439A1Ligands that have binding specificity for egfr and/or vegf and methods of use thereforDOMANTIS LTD·Filed 2006·Application pending·0 cites
- 3351US2004219643A1Dual-specific ligandFiled 2003·Application pending·0 cites
- 3450US2006257406A1LigandDOMANTIS LTD·Filed 2005·Application pending·0 cites
- 3548US2008241166A1Ligands that bind a receptorDOMANTIS LTD·Filed 2008·Application pending·0 cites
- 3647US2013041136A1Ligands that have binding specificity for egfr and/or vegf and methods of use thereforDOMANTIS LTD·Filed 2012·Application pending·0 cites
- 3743US2006280734A1RetargetingDOMANTIS LTD·Filed 2005·Application pending·0 cites
- 3842US2006083747A1Fc fusionDOMANTIS LTD·Filed 2005·Application pending·0 cites
- 3940US2013216538A1Compositions and Methods for Treating Inflammatory DisordersDOMANTIS LTD·Filed 2013·Application pending·0 cites
- 4038US2006073141A1Compositions and methods for treating inflammatory disordersDOMANTIS LTD·Filed 2005·Application pending·0 cites
- 4135US2011223168A1Ligand that has binding specificity for il-4 and/or il-13WINTER GREG·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Olga Ignatovich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →